findmyKOL

Antoine Makdissi, MD

Basic profile

University at Buffalo

ORCIDNone on fileNPI
RegionBuffalo, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2019Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Antoine Makdissi is an Endocrinology/Metabolic physician affiliated with University at Buffalo. OpenAlex indexes 70 publications with 1,738 citations (h-index 19).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
70publications

Distinct works indexed by OpenAlex.

1,738citations

Total citations across indexed works.

19h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3 Gates Cir
Buffalo, NY 142091120

Telephone

716-887-4069

Registry record last updated 23 Nov 2011.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    62.5%
    GLP-1 receptor agonist20.6%
    Ozempic47%Trulicity24%Mounjaro21%Rybelsus8%
    Part D120 patients
    Insulin Analog16.4%
    Lantus Solostar30%Humalog Kwikpen U-10018%Tresiba Flextouch U-1009%Novolog Flexpen7%Basaglar Kwikpen U-1007%Insulin Lispro Kwikpen U-1006%Tresiba Flextouch U-2005%Toujeo Max Solostar4%Humalog4%Toujeo Solostar3%Fiasp Flextouch3%Novolog2%Admelog Solostar1%Insulin Lispro1%
    Part D<11 patients

    + 8 more classes in this area

  • Cardiovascular

    20.4%
    Statin8.8%
    Atorvastatin Calcium64%Rosuvastatin Calcium28%Simvastatin8%
    Part D<11 patients
    Cholesterol absorption inhibitor2.8%
    Ezetimibe100%
    Part D47 patients

    + 7 more classes in this area

  • Hormonal (systemic)

    14.2%
    l-Thyroxine13.2%
    Levothyroxine Sodium83%Synthroid16%Levoxyl2%
    Part D<11 patients
    Thyroid Hormone Synthesis Inhibitor0.7%
    Methimazole100%
    Part D13 patients

    + 1 more class in this area

Where care is delivered (Part B)8.3% facility · 91.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”